)
Visual
test
Coya Therapeutics
Coya Therapeutics (COYA) investor relations material
Coya Therapeutics Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary16 Mar, 2026
Company overview and business model
Clinical-stage biotechnology company developing therapies to enhance regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases.
Lead asset COYA 302 is a Treg-enhancing biologic, combining low dose interleukin-2 and CTLA4-Ig, targeting neurodegenerative disorders such as ALS.
Pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, with both ex vivo and in vivo approaches.
Ongoing ALSTARS Phase 2 trial for COYA 302 in ALS; product not yet FDA approved.
Financial performance and metrics
Net losses of $21.2 million in 2025 and $14.9 million in 2024; accumulated deficit of $62.0 million as of December 31, 2025.
Operations funded primarily through private and public securities sales.
Received $7.5 million upfront from Dr. Reddy's in January 2024, with additional milestone and royalty payments possible.
Use of proceeds and capital allocation
No proceeds from this offering will go to the company; all shares are being resold by selling stockholders.
Company will pay registration-related legal and accounting fees.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Coya Therapeutics
- Clinical progress and financing extended cash runway into 2H 2027 despite higher net loss.COYA
Q4 202516 Mar 2026 - Treg-based therapies advance in neurodegeneration with promising data and major milestones ahead.COYAStatus update5 Mar 2026
- Lead asset advanced, promising FTD data, and major licensing deal set stage for 2026 growth.COYAEvercore ISI 8th Annual HealthCONx Conference3 Feb 2026
- LD IL-2 q4wks improved cognition and biomarkers in Alzheimer's, supporting Treg-based therapies.COYAStudy Update18 Jan 2026
- Advancing Treg-targeted biologics for ALS and Alzheimer's, with strong early data and funding.COYA7th Annual Evercore ISI HealthCONx Healthcare Conference12 Jan 2026
- Promising Treg-targeted therapies advance in ALS and FTD, backed by strong partnerships and trial data.COYAH.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025
- Offering up to $75M in securities to fund Treg-based therapy pipeline and corporate growth.COYARegistration Filing16 Dec 2025
- Registering 603,136 shares for resale after a $5M private placement; no proceeds to company.COYARegistration Filing16 Dec 2025
- Registering 1.38M shares for resale, the biotech faces ongoing losses and high clinical risk.COYARegistration Filing16 Dec 2025
Next Coya Therapeutics earnings date
Q1 20268 May, 2026
Coya Therapeutics
Next Coya Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage